Oncolytics Biotech (NASDAQ: ONCY) sets up $75M ATM facility

robot
Abstract generation in progress

Oncolytics Biotech Inc. has established an At-The-Market (ATM) offering facility, allowing it to sell up to $75 million of common stock through Jefferies LLC. The company plans to use the net proceeds to fund the clinical development of pelareorep, associated R&D, operating costs, and for general corporate purposes. This flexible fundraising mechanism leverages an existing S-3 shelf registration statement.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin